SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Zealand Pharma A/S (ZEAL) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+64.9%).
- Analyst consensus target $29.00 (+64.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 56/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ZEAL
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.31
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-26.54
Book Value / Share$0.00
Revenue / Share$7.62
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$29.00 (+64.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$1.60 |
$223.57M |
$36.37M |
16.3% |
| 2013 |
$-8.12 |
$6.57M |
$-183.68M |
-2794% |
| 2014 |
$-2.87 |
$153.77M |
$-64.99M |
-42.3% |
| 2015 |
$-4.82 |
$187.68M |
$-113.96M |
-60.7% |
| 2016 |
$-6.33 |
$234.78M |
$-153.91M |
-65.6% |
| 2017 |
$-9.77 |
$139.78M |
$-272.27M |
-194.8% |
| 2018 |
$18.94 |
$37.98M |
$581.28M |
1530.6% |
| 2019 |
$-16.91 |
$41.33M |
$-571.54M |
-1382.8% |
| 2020 |
$-22.07 |
$353.31M |
$-846.73M |
-239.7% |
| 2021 |
$-26.54 |
$292.57M |
$-1.02B |
-348% |
